Who are Paclitaxel (PTX)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Paclitaxel (Pac), Docetaxel (DOC), Standard of Care: Docetaxel, Paclitaxel, Epirubicin, Placebo plus Docetaxel, Cabazitaxel (XRP6258).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/paclitaxel-ptx.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Paclitaxel (PTX) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Paclitaxel (PTX) (Paclitaxel (PTX)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane; microtubule-stabilizing agent. Area: Oncology.

phase 3 Taxane; microtubule-stabilizing agent β-tubulin (microtubule) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Paclitaxel (PTX) (Paclitaxel (PTX)) — Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections. Paclitaxel stabilizes microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest in the G2/M phase, leading to cancer cell death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Paclitaxel (PTX) TARGET	Paclitaxel (PTX)	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	phase 3	Taxane; microtubule-stabilizing agent	β-tubulin (microtubule)
Paclitaxel (Pac)	Paclitaxel (Pac)	Aravive, Inc.	marketed	Taxane; microtubule stabilizer	β-tubulin / microtubules
Docetaxel (DOC)	Docetaxel (DOC)	Sun Yat-sen University	marketed	Taxane; microtubule stabilizer	β-tubulin
Standard of Care: Docetaxel	Standard of Care: Docetaxel	H. Lee Moffitt Cancer Center and Research Institute	marketed	Taxane; microtubule stabilizer	β-tubulin
Paclitaxel, Epirubicin	Paclitaxel, Epirubicin	Tianjin Medical University Cancer Institute and Hospital	marketed	Chemotherapy combination (taxane + anthracycline)	Microtubules (paclitaxel); Topoisomerase II and DNA (epirubicin)
Placebo plus Docetaxel	Placebo plus Docetaxel	Infinity Pharmaceuticals, Inc.	marketed	Taxane (microtubule stabilizer)	Microtubules (β-tubulin)
Cabazitaxel (XRP6258)	Cabazitaxel (XRP6258)	Sanofi	marketed	Taxane; microtubule stabilizer	β-tubulin (microtubule)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane; microtubule-stabilizing agent class)

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
M.D. Anderson Cancer Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Paclitaxel (PTX) — Competitive Intelligence Brief. https://druglandscape.com/ci/paclitaxel-ptx. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab